Floatz logo

N-DESMETHYL-4-HYDROXYTAMOXIFEN

Bipolar 1 Disorder

Jina Pharmaceuticals Inc.Small moleculePhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Bipolar 1 Disorder cohort.

Asset / SponsorPhaseRating
Asenapine
Organon and Co
Phase 3BBB
LAMOTRIGINE
Bristol-Myers Squibb
Phase 4BBB
Risperdal
Pakistan Institute of Medical Sciences
Phase 4BB
Clozapine
University of Texas Southwestern Medical Center
Phase 4BB
Endoxifen Enteric-Coated
Jina Pharmaceuticals Inc.
Phase 3B
SCYLLO-INOSITOL
OPKO Health, Inc.
Phase 2CCC
Valproic Acid
OPKO Health, Inc.
Phase 2CCC
Rap-219
Rapport Therapeutics Inc.
Phase 2CCC

Same molecule, other indications

N-DESMETHYL-4-HYDROXYTAMOXIFEN is also rated in:

bipolar I disorderDormant
B
Indicative ·
60 / 100
View asset →
invasive breast carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
estrogen-receptor positive breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →